Acadia Pharmaceuticals sell The Goldman Sachs Group, Inc.
Start price
07.08.25
/
50%
€20.93
Target price
07.08.26
€14.58
Performance (%)
-12.64%
Price
09:30
€18.29
Summary
This prediction is currently active. The prediction for Acadia Pharmaceuticals shows a convincing performance of -12.64%. This prediction currently runs until 07.08.26. The prediction end date can be changed by The_Goldman_Sachs_Gr at any time. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Acadia Pharmaceuticals | -3.200% | -3.200% |
| iShares Core DAX® | 0.444% | 3.030% |
| iShares Nasdaq 100 | 3.819% | 4.073% |
| iShares Nikkei 225® | 1.148% | 6.904% |
| iShares S&P 500 | 2.371% | 2.677% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Acadia Pharmaceuticals diskutieren
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $15.00 to $17.00. They now have a "sell" rating on the stock.
Ratings data for ACAD provided by MarketBeat